ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2465

Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α

Ikuko Masuda1,2, Kodo Okada3, Hisashi Yamanaka4 and Shigeki Momohara4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Rheumatology, Jyujyo Takeda Rehabilitation Hospital, Kyoto, Japan, 3SANSHO, Co. Ltd., Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cartilage, Lipids, Rheumatoid arthritis (RA), synovial cells, synovial fluid and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including i) antiproliferative effect on eukaryotic cell cycle, ii) regulation of Ca2+release, iii) regulation of actin rearrangement, iv) inhibition of tumor cell invasion. Furthermore, on human skin fibroblasts, cPA stimulates high molecular hyaluronic acid (HA) production through up-regulating HA synthase (HAS). cPA also has shown to have antinociceptive effect on animal models of acute and chronic pain. We have previously confirmed that cPA also stimulated HAS2 production on human osteoarthritic chondrocytes and synovial fibroblasts in vitro. Furthermore, we have shown that intra-articular administration of cPA suppressed pain, swelling, and articular cartilage degeneration in rabbit experimental osteoarthritis. These compelling results lead to a hypothesis that cPA may have direct role on anti-inflammation and protection of cartilage in arthritic condition. The aim of this study was to evaluate the effects of cPA on rheumatoid synovial fibroblasts which are under more severe inflammatory condition than osteoarthritis.

Methods: In vitro studies were performed using synovial fibroblasts obtained from rheumatoid arthritis patients at joint replacement surgery.  cPA 0-25 μM was added to synovial fibroblasts cultures and effects of cPA on synovial fibroblasts on HAS, HYAL, ADAMTS-4, ADAMTS-5, MMP-3, TIMP-3 expression were assessed at 24 and 48hrs by real time PCR using specific primers to corresponding genes. Synovial fibroblasts were also cultured with IL-1β and/or TNF-α, to study attenuated effect of cPA. Beta-actin was used as endogenous expression control. 

Results: cPA stimulated endogenous HA synthesis from synovial fibroblasts as time and dose-dependent manner in vitro. HAS2 gene was up-regulated as dose–dependent manner. IL-1β and/or TNF-α addition didn’t effect much on HAS2 expression, however addition of cPA stimulated HAS2 on synovial fibroblast with cytokines. On the other hand, cPA repressed HYAL-1 and HYAL-2 expression, and IL-1β (and/or TNF-α) stimulated HYAL-1 and -2, and cPA further repressed HYAL expression stimulated by cytokines. Not only with HYAL, cartilage degenerating enzymes, ADAMTS-4, ADAMTS-5, MMP-3 in synovial fibroblasts were all repressed by cPA, even after stimulated by cytokines.

Conclusion: The in vitro results confirmed that cPA had stimulatory effects on HA synthesis by rheumatoid synovial fibroblasts. The suppressing effect of HYAL, ADAMTS-4, ADAMTS-5, and MMP-3 on rheumatoid synovial fibroblasts by cPA shown here, might have played direct role to suppressing inflammation and also protecting articular cartilage of arthritic condition. Molecular mechanism of cPA to prevent cartilage degeneration remains to be elucidated, however, further study should be warranted for cPA as a novel candidate for therapeutic agent of arthritis.


Disclosure:

I. Masuda,

Teijin, Eizai, Tanabe Mitsubishi, Takeda, Bristol-Myer ,

8,

SANSHO Co. Ltd,

9;

K. Okada,
None;

H. Yamanaka,

Abbott, AbbVie, Asahikasei , Astellas, AstraZeneca, Bristol-Myers Squib, Chugai, Daiichi Sankyo, Eisai, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, MSD, Nippon Kayaku, Pfizer, Santen, Taishotoyama, Takeda, Teijin,

2,

Abbott, AbbVie, Astellas, AstraZeneca, Bristol-Myers Squib, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nippon Kayaku, Pfizer, Takeda, Teijin,

5,

Abbott, AbbVie, Astellas, Bristol-Myers Squib, Chugai, Eisai, Mitsubishi Tanabe, Pfizer, Takeda, Teijin,

8;

S. Momohara,

Abbvie Japan, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical,

8.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cyclic-phosphatidic-acid-cpa-suppresses-mmp-3-a-disintegrin-and-metalloproteinase-with-thrombospondin-motifsadamts-4-5-and-stimulates-has2-expression-in-inflammatory-rheumatoid-synovial-fibrobl/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology